MONTREAL, QC / ACCESSWIRE / June 18, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce a corporate name change and rebranding of the company to M2Bio Sciences, Inc ("M2Bio"). The name change was effective June 17, 2020, with the State of Nevada. In addition...
Read more
OTTAWA, ON / ACCESSWIRE / June 17, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today provides an update on the development of its ARDS-003 intravenous drug product for the potential treatment of cytokine release syndrome (CRS) and the potential prevention of Acute Respiratory Distress Syndrome...
Read more
Goal of XCART collaboration to optimize XCART process, develop manufacturing processes and to ultimately dose non-Hodgkin lymphoma (NHL) patients Pharmsynthez to act as primary contract research organization coordinating activities throughout collaboration Academic Institutions include: Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (IBCh RAS) Belarussian Research Center for...
Read moreENB-003 is the Company's first in class small molecule therapeutic selectively targeting the ETB receptor - a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / June 15, 2020 / ENB Therapeutics, INC., a biotechnology company pioneering a new and differentiated class of therapeutics targeting the ETB receptor (ETBR), today announced the successful completion of the first dosing cohort in a Phase I dose escalation of ENB-003 in...
Read more
TORONTO, ON / ACCESSWIRE / June 15, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received expedited approval from Health Canada to begin a Phase 2/3 clinical study of its investigational drug, EB05, which the company is developing as a potential treatment for moderate to severe COVID-19 patients. The company reported that it has EB05 drug product available now and is seeking government grants to...
Read more
Preferred Commerce Releases the Most Advanced Superoxide Dismutase (SOD) Product Line Worldwide With the Launch of Its THRIV5 Supplement Line Breakthrough formulation of SOD and additional key ingredients could boost the immune system beyond anything ever recorded. The THRIV5 product line could very well be the most powerful all-natural supplement to repair and help restore well-being in the human body. WELLINGTON, FL / ACCESSWIRE / June...
Read more
Mymetics Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine The European vaccine infrastructure, TRANSVAC2, funded by the European Commission through the Horizon 2020 framework, will provide Mymetics access to high quality technical vaccine development services in the fields of...
Read more
JUPITER, FL / ACCESSWIRE / June 10, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that it was selected by the...
Read more
MONTREAL, QC / ACCESSWIRE / June 10, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the signing of a distribution agreement with Medigrow Africa ("Medigrow"), an African based medical cannabis company with a formal network of legal African cannabis growers...
Read more
Contract No.: 36F797-20D0118 | Contract Term: Five Years FAIRFIELD, CT / ACCESSWIRE / June 9, 2020 / Calmare Therapeutics Incorporated, (OTC:CTTC), the pain mitigation company, was awarded a five-year, $2.5 million Federal Supply Schedule contract by the U.S. Department of Veteran Affairs for Calmare® Pain Therapy Devices. The contract was awarded under Schedule 65 II A - Medical Equipment and Supplies under Federal Supply Schedule...
Read more
This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Upon the publication of this Announcement, this inside information is now considered to be in the public domain. ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 9, 2020 / Midatech Pharma PLC (AIM:MTPH.L) (NASDAQ:MTP) (the "Company"), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of...
Read more
KEEGO HARBOR, MI / ACCESSWIRE / June 9, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and nutritional products derived from its proprietary algal cultures, announces today that the U.S. Patent and Trademark Office issued a Notice of Allowance for U.S. Patent application "Compounds and Methods for Affecting Cytokines" (Application Serial No....
Read more
NOTE: CEO Christopher Locher to Present at BIO Digital this week. LOWELL, MA / ACCESSWIRE / June 8, 2020 / Versatope Therapeutics, Inc, a biotechnology company developing vaccines and therapeutics, announced Christopher Locher, Ph.D., CEO of Versatope Therapeutics, Inc., will present at the 2020 BIO Digital Conference being held June 8-12, 2020. Click here to view the full multimedia, interactive announcement. Key...
Read more
BOSTON, MA / ACCESSWIRE / June 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, announced today that due to the public health impact of the COVID-19 pandemic and to support the health and well-being of its stockholders, the 2020 Annual Meeting, scheduled for...
Read more
Live video moderated discussion with CEO, Jeffrey Eisenberg, on Tuesday, June 16th at 12:00 PM ET, immediately followed by an interactive Q&A session FRAMINGHAM, MA / ACCESSWIRE / June 8, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific...
Read moreVANCOUVER, BC / ACCESSWIRE / June 5, 2020 / HemaGenetics Technologies Corp. (the "Company") is pleased to announce that it has set the share distribution record date for the Arrangement with 1207326 B.C. LTD., 1207331 B.C. LTD., 1207334 B.C. LTD., 1207335 B.C. LTD., 1207378 B.C. LTD., 1207380 B.C. LTD., 1207382 B.C. LTD., 1208614 B.C. LTD., 1209629 B.C. LTD., 1209631 B.C. LTD., 1210352 B.C. LTD., and 1211319 B.C. LTD....
Read more
Resumption of its PLENITUDE© clinical trial to bring QIXLEEF™ to market ReBorn© clinical trial to resume to bring CAUMZ™ to the market as an alternative to opioids for breakthrough pain QIXLEEF™ metabolite mapping ongoing OTTAWA, ON / ACCESSWIRE / June 5, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in...
Read more
LOS ANGELES, CA / ACCESSWIRE / June 4, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) through its subsidiary Pharma Tech Solutions, Inc. today made available CEO Keith Berman's recent interview on radio station CKNW, Vancouver's #1 rated News/Talk Radio station in the adult 35-64 sector. Berman appeared LIVE with talk show host John Daly on his "Daly Back on the Beat," Show and discussed the Decision Diagnostics GenViro!...
Read more
OTTAWA, ON / ACCESSWIRE / June 4, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development and Storz & Bickel, a subsidiary of Canopy Growth Corporation, (TSX:WEED)(NYSE:CGC), a world-leading diversified cannabis, hemp and cannabis device company, are pleased to announce that they have finalized a...
Read more
MONTREAL, QC / ACCESSWIRE / June 3, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the newly appointed members of the Company. Mr. Johann McLoughlin hails from the creative hub of Cape Town, South Africa. He joins Wuhan effective immediately as Director of Product...
Read more
